全文获取类型
收费全文 | 392701篇 |
免费 | 37389篇 |
国内免费 | 27223篇 |
专业分类
耳鼻咽喉 | 3066篇 |
儿科学 | 5321篇 |
妇产科学 | 4322篇 |
基础医学 | 42132篇 |
口腔科学 | 6742篇 |
临床医学 | 54597篇 |
内科学 | 50380篇 |
皮肤病学 | 4550篇 |
神经病学 | 18262篇 |
特种医学 | 14956篇 |
外国民族医学 | 224篇 |
外科学 | 35100篇 |
综合类 | 77049篇 |
现状与发展 | 93篇 |
一般理论 | 31篇 |
预防医学 | 29388篇 |
眼科学 | 10852篇 |
药学 | 43252篇 |
448篇 | |
中国医学 | 26674篇 |
肿瘤学 | 29874篇 |
出版年
2024年 | 764篇 |
2023年 | 5117篇 |
2022年 | 9442篇 |
2021年 | 18221篇 |
2020年 | 15062篇 |
2019年 | 12042篇 |
2018年 | 12584篇 |
2017年 | 12359篇 |
2016年 | 11214篇 |
2015年 | 17726篇 |
2014年 | 22225篇 |
2013年 | 20787篇 |
2012年 | 30685篇 |
2011年 | 34506篇 |
2010年 | 23850篇 |
2009年 | 19630篇 |
2008年 | 23582篇 |
2007年 | 23200篇 |
2006年 | 22050篇 |
2005年 | 20684篇 |
2004年 | 13814篇 |
2003年 | 13119篇 |
2002年 | 10784篇 |
2001年 | 9245篇 |
2000年 | 8942篇 |
1999年 | 8577篇 |
1998年 | 5306篇 |
1997年 | 5119篇 |
1996年 | 3923篇 |
1995年 | 3740篇 |
1994年 | 3158篇 |
1993年 | 2044篇 |
1992年 | 2435篇 |
1991年 | 2142篇 |
1990年 | 1803篇 |
1989年 | 1567篇 |
1988年 | 1287篇 |
1987年 | 1157篇 |
1986年 | 954篇 |
1985年 | 683篇 |
1984年 | 371篇 |
1983年 | 272篇 |
1982年 | 149篇 |
1981年 | 171篇 |
1980年 | 115篇 |
1979年 | 155篇 |
1978年 | 74篇 |
1977年 | 54篇 |
1974年 | 42篇 |
1972年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
41.
42.
目的探讨中国9个城市(简称九市)4~7岁儿童乳恒牙替换及其与体格生长的关系,分析恒牙发育长期变化趋势。方法采用分层整群抽样的方法,以4~7岁儿童为调查对象,于2015年6—10月在北京、哈尔滨、西安(北片),上海、南京、武汉(中片),广州、福州、昆明(南片)九市进行横断面调查,共37973名儿童,其中男19035名,女18938名。6岁以下每6个月为1组,6~<7岁1岁为1组。现场检查乳牙脱落、恒牙萌出情况,测量身高、体重等,并依据2009年中国儿童生长标准计算体格指标Z分值。采用Probit概率单位回归方法计算换牙年龄。不同性别、地区、年龄分组组间比较采用χ2检验或t检验。并利用1995年中国九市儿童体格发育调查中乳恒牙替换相关数据,分析恒牙发育的长期变化趋势。结果九市37973名儿童随着年龄增长换牙率逐渐增加,从4.0~<4.5岁的0.6%(42/7568)增长至5.5~<6.0岁的30.3%(2295/7583),6.0~<7.0岁达到74.5%(5680/7627)。除4.0~4.5岁组外,无论城郊男童换牙率均低于女童(P均<0.05);城区换牙率(男5.5~<6.0岁、女4.5~<5.0岁组之后)略高于郊区,如6.0~<7.0岁组男童城郊分别为74.2%(1427/1924)、69.2%(1305/1885)(χ2=11.446,P<0.01)。九市儿童换牙年龄为6.00(95%CI:5.98~6.01)岁。换牙年龄的第3~97百分位变化范围为4.88~7.11岁。女童中位换牙年龄(5.94岁)早于男童(6.06岁);城区(5.94岁)早于郊区(6.05岁);北片(5.97岁)、中片地区(5.97岁)略早于南片地区(6.05岁)。已换牙儿童体重、身高、体质指数Z分值均高于未换牙儿童(0.35±1.17比0.03±1.13、0.32±1.00比0.03±1.02、0.23±1.16比0.04±1.13,t=20.81、21.67、12.09,P均<0.05)。与1995年相比,2015年5.0岁以后儿童换牙率明显提高,如城区男童6.0~<7.0岁组1995年为63.8%(1146/1796),2015年提高至74.2%(1427/1924)(χ2=46.748,P<0.01);中位换牙年龄2015年较1995年提前0.24岁。结论九市4~7岁儿童换牙年龄女童早于男童,城区早于郊区,北、中片早于南片地区。换牙早晚与体格生长水平有关。近20年换牙年龄存在小幅提前趋势。 相似文献
43.
44.
Huang Liyan Li Wei Li Yi Song Chaoyuan Wang Pin Wang Hongchun Sun Xiulian 《Neurogenetics》2020,21(1):39-49
neurogenetics - Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common monogenic disease leading to stroke and vascular dementia.... 相似文献
45.
Jiao-Tian Xu Yuan Qian Wei Wang Xiao-Xiang Chen Yang Li Yu Li Zhi-Yong Yang Xiao-Bin Song Di Lu Xing-Li Deng 《中国神经再生研究》2020,(1):112-119
Previous studies have shown that neural stem cell transplantation has the potential to treat Parkinson’s disease,but its specific mechanism of action is still unclear.Stromal cell-derived factor-1 and its receptor,chemokine receptor 4(CXCR4),are important regulators of cell migration.We speculated that the CXCR4/stromal cell-derived factor 1 axis may be involved in the therapeutic effect of neural stem cell transplantation in the treatment of Parkinson’s disease.A Parkinson’s disease rat model was injected with 6-hydroxydopamine via the right ascending nigrostriatal dopaminergic pathway,and then treated with 5μL of neural stem cell suspension(1.5×104/L)in the right substantia nigra.Rats were intraperitoneally injected once daily for 3 days with 1.25 mL/kg of the CXCR4 antagonist AMD3100 to observe changes after neural stem cell transplantation.Parkinson-like behavior in rats was detected using apomorphine-induced rotation.Immunofluorescence staining was used to determine the immunoreactivity of tyrosine hydroxylase,CXCR4,and stromal cell-derived factor-1 in the brain.Using quantitative real-time polymerase chain reaction,the mRNA expression of stromal cell-derived factor-1 and CXCR4 in the right substantia nigra were measured.In addition,western blot assays were performed to analyze the protein expression of stromal cell-derived factor-1 and CXCR4.Our results demonstrated that neural stem cell transplantation noticeably reduced apomorphine-induced rotation,increased the mRNA and protein expression of stromal cell-derived factor-1 and CXCR4 in the right substantia nigra,and enhanced the immunoreactivity of tyrosine hydroxylase,CXCR4,and stromal cell-derived factor-1 in the brain.Injection of AMD3100 inhibited the aforementioned effects.These findings suggest that the stromal cell-derived factor-1/CXCR4 axis may play a significant role in the therapeutic effect of neural stem cell transplantation in a rat model of Parkinson’s disease.This study was approved by the Animal Care and Use Committee of Kunming Medical University,China(approval No.SYXKK2015-0002)on April 1,2014. 相似文献
46.
47.
目的 初步评估IMRT对无法手术ⅣA期胸腺瘤的疗效及安全性。方法 回顾分析2010-2017年间15例无法手术接受IMRT的ⅣA期胸腺瘤患者,其中男9例、女6例,中位数59岁。PTV、CTV、GTV放疗剂量分别为50、60、70Gy分15~20次,分析近期疗效、总生存率及不良反应。结果 中位随访时间48个月,近期部分缓解率93%(14/15),1、3、5年总生存率分别为100%、75%、75%,仅1例出现3级血液系统反应。4例死亡患者均为肿瘤相关死亡。结论 初步证明ⅣA期胸腺瘤IMRT疗效较好、安全性高,可作为无法手术治疗的胸腺瘤患者安全、有效的治疗手段。 相似文献
48.
Bo Cai Qiyun Sun Jianhui Qiao Changlin Yu Kaixun Hu Tieqiang Liu Bingxia Li Yajing Huang Yi Wang Hongli Zuo Zheng Dong Yaqing Lei Zhiqing Liu Bo Yao Caixia Li Huisheng Ai Mei Guo 《American journal of cancer research》2020,10(11):3852
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis, and the efficacy of chemotherapy plus tyrosine kinase inhibitors (TKIs) followed by mismatched donor stem cell infusion (microtransplantation, MST) has not been determined. We retrospectively summarized 45 patients including 11 undergoing MST with TKIs, 17 receiving allogeneic transplant and 17 undergoing chemotherapy with TKIs. Improved 4-year overall survival rate was observed in the MST group (91%) compared with either transplant group (31%, P = .005) or chemotherapy group (36%, P = .013). The MST group also had higher 2-year and 4-year leukemia-free survival rates (91% and 72%, respectively) compared with either transplant group (33%, P = .005 and 33%, P = .021, respectively) or chemotherapy group (41%, P = .017 and 31%, P = .023, respectively). 2-year and 4-year cumulative incidences of hematologic relapse were lower in the MST group (9% and 28%, respectively) compared with those in the chemotherapy group (56%, P = .025 and 67%, P = .034, respectively). In patients undergoing MST, donor microchimerism was detected (1.07 × 10-5 to 6.6 × 10-4 copies from 9 to 1499 days) in 7 patients, and donor/patient-derived HLA*0201/2402+WT1+CD8+ T cells were found from 0.05% to 0.67% in 6 patients. MST may provide a favorable treatment for patients with Ph+ ALL. 相似文献
49.
50.